Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2009, for Altria Group, Inc. The company operates primarily through its wholly-owned subsidiaries: Philip Morris USA Inc. (cigarettes and smokeless products), UST LLC (smokeless products and wine, acquired January 6, 2009), and John Middleton Co. (cigars). Additionally, Altria holds a 27.4% equity interest in SABMiller plc. The reporting period reflects the integration of UST and the impact of the April 2009 federal excise tax increase on tobacco products.
Key Financial Metrics
| Metric (in millions, except per share) | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Net Revenues | $11,242 | $9,464 |
| Gross Profit | $4,498 | $3,728 |
| Operating Income | $2,868 | $2,555 |
| Earnings from Continuing Operations | $1,600 | $1,544 |
| Net Earnings (Attributable to Altria) | $1,599 | $3,384 |
| Diluted EPS (Continuing Ops) | $0.77 | $0.73 |
| Diluted EPS (Net Earnings) | $0.77 | $1.61 |
| Cash and Cash Equivalents | $544 | $7,916 |
| Total Debt (Consumer Products) | $12.4 billion | $7.0 billion |
| Net Cash Provided by Operating Activities | $135 | $(446) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 18.8% to $11.2 billion, driven by the UST acquisition, higher pricing due to federal excise tax increases, and growth in the financial services segment.
- Net Earnings Decline: Net earnings attributable to Altria decreased 52.7% to $1.6 billion. This decline is primarily due to the spin-off of Philip Morris International (PMI) in March 2008, which resulted in $1.9 billion of earnings from discontinued operations in the prior year period.
- Continuing Operations Growth: Earnings from continuing operations increased 3.6% to $1.6 billion, reflecting higher operating income and SABMiller gains, partially offset by increased interest expense.
- Debt Increase: Total consumer products debt rose to $12.4 billion from $7.0 billion, primarily due to the issuance of $4.2 billion in long-term notes to finance the UST acquisition.
- Cash Position: Cash and cash equivalents decreased significantly to $544 million from $7.9 billion, largely due to the $10.2 billion cash outlay for the UST acquisition.
Guidance, Outlook, and Risks
- 2009 Guidance: Altria raised its full-year 2009 diluted EPS guidance from continuing operations to a range of $1.51 to $1.56 (previously $1.47 to $1.52). This reflects higher projected earnings and a net gain in SABMiller-related items.
- Adjusted EPS: Management projects 2009 adjusted diluted EPS from continuing operations to grow 4% to 7% over 2008, excluding net charges of $0.21 per share related to exit costs, UST acquisition costs, and SABMiller impairments.
- Share Repurchases: The $4.0 billion share repurchase program was suspended in January 2009 to preserve financial flexibility and protect credit ratings. No shares were repurchased under the program in Q2 2009.
- Key Risks:
- Litigation: Significant exposure to tobacco-related litigation, including "Lights/Ultra Lights" class actions and health care cost recovery suits. Management believes losses are not probable or estimable for most pending cases.
- Regulation: The Family Smoking Prevention and Tobacco Control Act (signed June 2009) grants the FDA broad authority to regulate tobacco products, potentially increasing compliance costs and restricting marketing.
- IRS Challenges: The IRS has disallowed tax benefits for certain leveraged lease transactions (1996-1999) and indicated intent to challenge 2000-2003 transactions, potentially resulting in $1.0 billion in disallowed tax benefits.
- Volume Declines: Cigarette shipment volumes declined 10.4% year-over-year, attributed to federal tax increases and competitive price gaps.
Investor Verification Checklist
- Verify the impact of the UST acquisition on future cash flows and the realization of projected $300 million in annual synergies by 2011.
- Monitor the status of IRS challenges regarding PMCC leveraged leases and potential tax liabilities exceeding $1 billion.
- Assess the financial impact of the new FDA regulations on marketing restrictions, product design, and user fees.
- Review the litigation bond requirements and potential settlements related to "Lights/Ultra Lights" and health care cost recovery cases.
- Confirm the trajectory of cigarette volume declines relative to the industry average and the effectiveness of pricing strategies in offsetting volume loss.